Back HCV Treatment

HCV Treatment

CROI 2014: The Role of Interferon in HIV Response [VIDEO]

Although interferon is on its way out as a standard of care for hepatitis C, researchers are learning more about its role in HIV, conference vice chair Julie Overbaugh said at a media briefing on the opening day of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Read more:

CROI 2014: Hepatitis C Treatment in the Real World [VIDEO]

The opening day of the 21st Conference on Rtroviruses and Opportuistic Infections (CROI 2014) featured a press conference on advances in the treatment of hepatitis C, with a focus on how new drugs may be used in the real world, given barriers such as high cost and a shortage of experienced medical providers.

alt

Read more:

Daclatasvir and Asunaprevir Designated as Hepatitis C "Breakthrough" Therapy

Bristol-Myers Squibb's dual regimen containing the hepatitis C virus NS5A inhibitor daclatasvir plus the HCV protease inhibitor asunaprevir has been granted "breakthrough therapy" status by the U.S. Food and Drug Administration, putting in on track for rapid approval, the company announced this week.

alt

Read more:

CROI 2014: Retrovirus Conference Starts Monday in Boston

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) will take place next week, March 3-6, at the Hynes Convention Center in Boston. HIVandHepatitis.com will be on site all week to bring you the latest news coverage about HIV, hepatitis C, and related topics.

alt

Read more:

Daclatasvir + Asunaprevir Works Well for HCV 1b, but 1a Requires Interferon

An all-oral combination of Bristol-Myers Squibb's daclatasvir plus asunaprevir cured nearly 80% of patients with genotype 1b hepatitis C virus (HCV), but people with harder-to-treat HCV subtype 1a needed to add pegylated interferon and ribavirin to achieve high sustained response rates, researchers reported in the March 2014 Journal of Hepatology.

alt

Read more: